Render Target: STATIC
Render Timestamp: 2024-12-26T12:18:05.127Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-04-05 20:52:42.346
Product last modified at: 2024-08-08T23:30:07.845Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human IGF-I Recombinant Protein #29608

    Product Information

    Storage

    Human IGF-I Recombinant Protein is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/mL which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage.

    Once in solution, store at 4°C and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles if storing reconstituted material at -20ºC to -80ºC.

    Product Description

    MW (kDa) 7.7
    Purity A greater than or equal to 95% purity was determined by SDS-PAGE.
    Endotoxin Endotoxin levels are less than or equal to 1 EU / 1 μg hIGF-I.
    Activity The bioactivity of recombinant hIGF-I was determined in an FDC-P1 cell proliferation assay. The ED50 of each lot is less than or equal to 10 ng/mL.

    Source / Purification

    Recombinant human IGF-I was expressed in E. coli and is supplied in a lyophilized form.

    Background

    Most circulating endocrine acting IGF-I is produced by hepatocytes, and paracrine or autocrine acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes, including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I and most inhibit IGF-I binding to IGF-I receptor (IGF-IR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGF-IR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGF-IR are frequently expressed by cancer cells and may contribute to the proliferation and viability of several cancer types (1,2).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.